Pablo Morentin Gutierrez

722 total citations
22 papers, 402 citations indexed

About

Pablo Morentin Gutierrez is a scholar working on Molecular Biology, Biochemistry and Oncology. According to data from OpenAlex, Pablo Morentin Gutierrez has authored 22 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Biochemistry and 5 papers in Oncology. Recurrent topics in Pablo Morentin Gutierrez's work include Lipid metabolism and biosynthesis (5 papers), Hormonal Regulation and Hypertension (4 papers) and Immune Cell Function and Interaction (3 papers). Pablo Morentin Gutierrez is often cited by papers focused on Lipid metabolism and biosynthesis (5 papers), Hormonal Regulation and Hypertension (4 papers) and Immune Cell Function and Interaction (3 papers). Pablo Morentin Gutierrez collaborates with scholars based in United Kingdom, Sweden and Singapore. Pablo Morentin Gutierrez's co-authors include Marcelo Radisic, Kevin Hudson, Frederick W. Goldberg, Molly A. Taylor, James S. Scott, Simon T. Barry, Larissa S. Carnevalli, Lorraine Mooney, Sam D. Groombridge and Anna Coenen-Stass and has published in prestigious journals such as Blood, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Pablo Morentin Gutierrez

21 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pablo Morentin Gutierrez United Kingdom	11	140	91	81	71	58	22	402
Kiyomi Yamauchi Japan	9	118 0.8×	104 1.1×	26 0.3×	78 1.1×	73 1.3×	9	513
Xiaofang Guo China	13	188 1.3×	83 0.9×	27 0.3×	26 0.4×	33 0.6×	35	388
Van N. Michalek United States	11	338 2.4×	49 0.5×	30 0.4×	33 0.5×	41 0.7×	20	598
Daniel LaSala United States	11	202 1.4×	50 0.5×	19 0.2×	126 1.8×	38 0.7×	17	454
José Alfón Spain	10	119 0.8×	37 0.4×	91 1.1×	23 0.3×	99 1.7×	28	490
Helen Galczenski United States	9	171 1.2×	34 0.4×	19 0.2×	15 0.2×	113 1.9×	9	438
Leslie J. Askonas United States	10	116 0.8×	47 0.5×	21 0.3×	61 0.9×	29 0.5×	14	309
Jill Skepner United States	7	212 1.5×	164 1.8×	34 0.4×	34 0.5×	390 6.7×	7	690
Raffaele Raucci Italy	12	144 1.0×	75 0.8×	77 1.0×	17 0.2×	52 0.9×	17	352
Yumiko Nakagawa Japan	8	165 1.2×	50 0.5×	49 0.6×	53 0.7×	113 1.9×	17	389

Countries citing papers authored by Pablo Morentin Gutierrez

Since Specialization

Citations

This map shows the geographic impact of Pablo Morentin Gutierrez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Morentin Gutierrez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Morentin Gutierrez more than expected).

Fields of papers citing papers by Pablo Morentin Gutierrez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Morentin Gutierrez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Morentin Gutierrez. The network helps show where Pablo Morentin Gutierrez may publish in the future.

Co-authorship network of co-authors of Pablo Morentin Gutierrez

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Morentin Gutierrez. A scholar is included among the top collaborators of Pablo Morentin Gutierrez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Morentin Gutierrez. Pablo Morentin Gutierrez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gutierrez, Pablo Morentin, et al.. (2023). An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions. Journal of Pharmacokinetics and Pharmacodynamics. 50(5). 327–349. 10 indexed citations

Carnevalli, Larissa S., Molly A. Taylor, Matthew King, et al.. (2021). Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular Cancer Therapeutics. 20(6). 1080–1091. 14 indexed citations

Konopleva, Marina, Nitin Jain, Courtney L. Andersen, et al.. (2021). NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies. Blood. 138(Supplement 1). 2353–2353. 5 indexed citations

Scott, James S., Tom Moss, Christopher J. Morrow, et al.. (2020). Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD). Cancer Research. 80(16_Supplement). 5674–5674. 11 indexed citations

Gutierrez, Pablo Morentin, Christopher J. Morrow, Mandy Lawson, et al.. (2020). Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development. Cancer Research. 80(16_Supplement). 4369–4369.

Gangl, Eric T., Petar Pop-Damkov, Pablo Morentin Gutierrez, et al.. (2020). Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. Cancer Research. 80(16_Supplement). 1042–1042. 6 indexed citations

Gutierrez, Pablo Morentin, et al.. (2019). Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol. Pharmacology Research & Perspectives. 7(2). e00465–e00465. 7 indexed citations

Carnevalli, Larissa S., Michele Moschetta, Pablo Morentin Gutierrez, et al.. (2019). Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models. Cancer Research. 79(13_Supplement). 100–100. 2 indexed citations

Carnevalli, Larissa S., Charles Sinclair, Molly A. Taylor, et al.. (2018). PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. Journal for ImmunoTherapy of Cancer. 6(1). 158–158. 71 indexed citations

10.

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2016). Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers. Molecular Cancer Therapeutics. 15(5). 877–889. 36 indexed citations

11.

Gutierrez, Pablo Morentin, John G. Swales, Jan W. Eriksson, et al.. (2015). Continuous inhibition of 11β‐hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice. British Journal of Pharmacology. 172(20). 4806–4816. 7 indexed citations

12.

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2015). Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers. Cancer Research. 75(15_Supplement). 2665–2665. 1 indexed citations

13.

Gabrielsson, Johan, Stephan Hjorth, Barbara Vogg, et al.. (2014). Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples. European Journal of Pharmaceutical Sciences. 67. 144–159. 9 indexed citations

14.

Harno, Erika, Elizabeth C. Cottrell, Alice Yu, et al.. (2013). 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors Still Improve Metabolic Phenotype in Male 11β-HSD1 Knockout Mice Suggesting Off-Target Mechanisms. Endocrinology. 154(12). 4580–4593. 27 indexed citations

15.

Buckett, Linda K., Öjvind Davidsson, Hans Emtenäs, et al.. (2013). Identification and design of a novel series of MGAT2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(9). 2721–2726. 25 indexed citations

16.

Plowright, Alleyn T., Peter Barton, Alan M. Birch, et al.. (2012). Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1. MedChemComm. 4(1). 151–158. 4 indexed citations

17.

Goldberg, Frederick W., Alan M. Birch, Andrew G. Leach, et al.. (2012). Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors. MedChemComm. 4(1). 165–174. 2 indexed citations

18.

Waring, Michael J., Alan M. Birch, Susan Birtles, et al.. (2012). Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1 – the discovery of AZD2353. MedChemComm. 4(1). 159–164. 7 indexed citations

19.

Goldberg, Frederick W., Andrew G. Leach, James S. Scott, et al.. (2012). Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors. Journal of Medicinal Chemistry. 55(23). 10652–10661. 29 indexed citations

20.

Radisic, Marcelo, et al.. (2000). Severe Acute Lung Injury Caused byMycoplasma pneumoniae: Potential Role for Steroid Pulses in Treatment. Clinical Infectious Diseases. 31(6). 1507–1511. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact